Institutional Repository (UniKL IR)
Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/26283
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNur Haifa Amani Zulkiply-
dc.contributor.authorVignesh, Ramachandran-
dc.contributor.authorMuthukumarasamy, Ravindran-
dc.contributor.author(UniKL RCMP)-
dc.date.accessioned2022-11-14T04:34:25Z-
dc.date.available2022-11-14T04:34:25Z-
dc.date.issued2021-07-
dc.identifier.citationNur Haifa Amani Zulkiply, Vignesh, R., & Muthukumarasamy, R. (2021). A Narrative Review on the Effectiveness of Tocilizumab in Reducing the Mortality Risk in COVID-19 Patients. Malaysian Journal of Medicine and Health Sciences, 17(3), 2636–9346. https://medic.upm.edu.my/upload/dokumen/2021062816053138_MJMHS_0854.pdfen_US
dc.identifier.issn16758544-
dc.identifier.urihttps://medic.upm.edu.my/jurnal_kami/penerbitan/mjmhs_vol_17_no_3_july_2021-62220-
dc.identifier.urihttp://hdl.handle.net/123456789/26283-
dc.description.abstractThe novel coronavirus disease 2019 (COVID-19) has reached its pandemic scale within a short period of its first case reported in Wuhan, China in December 2019, leading to a great economic crisis all over the world. As of today, there is no clinically approved antiviral drug available for the treatment of COVID-19. Tocilizumab, a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor, clinically approved for the treatment of rheumatoid arthritis, is one such drug used to manage the COVID-19 symptoms. The current study reviews the effectiveness of Tocilizumab as a treatment option for COVID-19. Research findings on Tocilizumab are effective in COVID-19 patients with the risk of cytokine storm and further complications. Nevertheless, this review also recommends further investigation on the effectiveness of this drug with a large group of patients for more accuracy in results with COVID 19 patientsen_US
dc.language.isoenen_US
dc.publisherUniversiti Putra Malaysia Pressen_US
dc.subjectCOVID-19en_US
dc.subjectCytokine stormen_US
dc.subjectInterleukin-6 inhibitorsen_US
dc.subjectSARS-CoV-2en_US
dc.subjectTocilizumaben_US
dc.titleA narrative review on the effectiveness of tocilizumab in reducing the mortality risk in covid-19 patientsen_US
dc.typeArticleen_US
Appears in Collections:Journal Articles

Files in This Item:
File Description SizeFormat 
A narrative review on the effectiveness of tocilizumab in reducing the mortality risk in covid-19 patients .pdf353.38 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.